BCR and acute lymphoblastic leukemia: In conclusion, second and third-generation TKIs could be effective in patients with recurrent Ph+ ALL, while multidrug-resistant compound mutations within the BCR-ABL1 kinase domain are an emerging clinical problem for patients receiving sequential TKIs therapy.